Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 14/20 | 0.79 |
| ▸ | NPC1 | O15118 | 12/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.79 |
| ▸ | PKM | P14618 | 6/20 | 0.79 |
| ▸ | HPGD | P15428 | 4/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.79 |
| ▸ | TSHR | P16473 | 2/20 | 0.79 |
| ▸ | TP53 | P04637 | 2/20 | 0.79 |
| ▸ | GFER | P55789 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | MIF | P14174 | 1/20 | 0.69 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | CLK1 | P49759 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12848509 | 0.99 | RAB9A (0.76) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL6389879 | 0.87 | RAB9A (0.97) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL8342931 | 0.84 | RAB9A (0.78) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| Bromide SCHEMBL3629507 | 0.84 | RAB9A (0.57) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4728739 | 0.82 | RAB9A (1.00) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL3628740 | 0.82 | RAB9A (0.57) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL16212338 | 0.81 | SUV39H2 (0.58) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL10242020 | 0.81 | RAB9A (0.76) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4728826 | 0.81 | RAB9A (0.76) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4780900 | 0.81 | RAB9A (0.76) | RAB9ANPC1KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895599-B2 | Lipoprotein lipase-activating compositions comprising benzene derivates | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20130296342-A1 | LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2013-11-07 | — | — | US | disclosed |
| EP-2280706-B1 | LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20110065728-A1 | LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296342-A1 | LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATES | LPL, LIPC, LIPE | RAB9A 3933/4885NPC1 366/4885KDM4E 1225/4885 |
| US-20110065728-A1 | LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES | LPL, LIPC, LIPE | RAB9A 3849/4885NPC1 334/4885KDM4E 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.